This information is intended for use by health professionals

1. Name of the medicinal product

Morphine Sulfate 10 mg/ml solution for injection

2. Qualitative and quantitative composition

Each ml of solution for injection contains 10 mg Morphine Sulfate

Excipient with known effect:

This medicine contains a maximum of 3.3 mg of sodium per each 1 ml ampoule.

For the full list of excipients, see section 6.1

3. Pharmaceutical form

Solution for injection

4. Clinical particulars
4.1 Therapeutic indications

Analgesic for severe and very severe pain.

4.2 Posology and method of administration

Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with morphine in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).

Morphine injection may be administered subcutaneously, intramuscularly or intravenously.

Dosage should be adjusted according to the severity of the pain and the response of the patient.

Appropriate starting doses are as follows:


Adults and adolescents over 12 years



Subcutaneously, intramuscularly

5 - 20 mg

Individuals might require considerably higher doses for sufficient relief of pain. In general, the minimum effective dose should be administered.

For intravenous administration it is important to inject morphine slowly over a period of 4 to 5 minutes with the patient in the recumbent position.

For continuous intravenous infusion of morphine, appropriate starting doses are 1-2 mg per hour in adults and adolescents over 12 years. Daily doses will not usually exceed 100 mg per day in adults and adolescents over 12 years, however, in cancer patients chronic administration of higher doses up to 4 g per day may occasionally be required.

Discontinuation of therapy

Withdrawal (abstinence) syndrome may be precipitated if opioid administration is suddenly discontinued (See Section 4.4). Therefore the dose should be gradually reduced prior to discontinuation.

Children under 12 years

This formulation is not recommended for use in children under 12 years.

In the Elderly

The dose of morphine should be reduced in elderly patients and titrated to provide optimal pain relief with minimal side effects. Morphine clearance decreases and half-life increase in older patients.

In patients with disturbed Renal Function

Caution should be exercised in the use of Morphine in patients with renal dysfunction i.e. renal failure, because such patients can show signs of overdose following conservative dosage regimens.

In patients with impaired Liver Function

Caution should be exercised in the use of Morphine in patients with impaired liver function e.g. cirrhosis as this condition is likely to affect elimination. The dose therefore should be carefully titrated to provide optimal pain relief.

4.3 Contraindications

• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

• Respiratory depression or insufficiency

• Obstructive airways disease

• Cerebral trauma

• Increased intracranial pressure

• Coma

• Convulsive disorders

• Acute alcoholism

• Renal failure

• Ureteral stenosis

• Pancreatitis

• Liver failure

• Gall-bladder dysfunction

• Ileus

• Inflammatory bowel disease

• Hypotension with hypovolaemia

• Prostatic hypertrophy

• Myxoedema

• Phaeochromocytoma

• Concurrent administration of MAO inhibitors or within two weeks of discontinuation of their use.

4.4 Special warnings and precautions for use

Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs

Concomitant use of morphine and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe morphine concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.

The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).

Drug dependence, tolerance and potential for abuse

For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g., major depression).

Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.

A comprehensive patient history should be taken to document concomitant medications, including over- the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.

Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance.

The risks of developing tolerance should be explained to the patient.

Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.

Patients should be closely monitored for signs of misuse, abuse or addiction. The clinical need for analgesic treatment should be reviewed regularly.

Drug withdrawal syndrome

Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with morphine.

Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.

The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.

If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.


Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain.

This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.

Acute chest syndrome (ACS) in patients with sickle cell disease (SCD)

Due to a possible association between ACS and morphine use in SCD patients treated with morphine during a vaso-occlusive crisis, close monitoring for ACS symptoms is warranted.

Adrenal insufficiency

Opioid analgesics may cause reversible adrenal insufficiency requiring monitoring and glucocorticoid replacement therapy. Symptoms of adrenal insufficiency may include e.g. nausea, vomiting, loss of appetite, fatigue, weakness, dizziness, or low blood pressure.

Decreased Sex Hormones and increased prolactin

Long-term use of opioid analgesics may be associated with decreased sex hormone levels and increased prolactin. Symptoms include decreased libido, impotence or amenorrhea.


Plasma concentrations of morphine may be reduced by rifampicin. The analgesic effect of morphine should be monitored and doses of morphine adjusted during and after treatment with rifampicin (see section 4.5).

Other conditions/situations in which morphine should be used with caution

Hypotension, hypothyroidism, asthma (avoid during attack), and decreased respiratory reserve; pregnancy and breast-feeding (see section 4.6); treatment may precipitate coma in hepatic impairment (reduce dose but many such patients tolerate morphine well – see section 4.2); reduce dose in renal impairment, elderly and debilitated patients (see section 4.2).

Sodium content

This medicine contains less than 1 mmol sodium (23 mg) per each 1 ml ampoule, that is to say essentially 'sodium-free'.

4.5 Interaction with other medicinal products and other forms of interaction

• Sedative medicines such as benzodiazepines or related drugs:

The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4).

• Other CNS depressants: In patients concurrently receiving other central nervous system depressants (including sedatives, hypnotics, general anaesthetics, phenothiazines, other tranquillisers and alcohol) morphine should be used with caution and in reduced dosage because of the risk of respiratory depression, hypotension and profound sedation or coma.

• Muscle relaxants: Morphine may enhance the neuromuscular blocking action of skeletal muscle relaxants.

• Mixed agonist/ antagonist opioid analgesics: Mixed agonist/antagonist opioid analgesics (e.g. pentazocine, nalbuphine, and buprenorphine) can reduce the analgesic effect of morphine by competitive blocking of the receptor. Therefore these drugs should not be administered to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic.

• Monoamine oxidase inhibitors (MAOIs): MAOIs intensify the effect of morphine and other opioid drugs. Severe and even fatal events (e.g. anxiety, confusion and significant depression of respiration, sometimes leading to coma) have been observed with co-administration of both drugs. Morphine should not be given to patients taking MAOIs or within 14 days of stopping such treatment.

• Cimetidine: Higher plasma concentrations of morphine due to decreased metabolism of morphine have been observed with co-administration of cimetidine. Confusion and severe respiratory depression were reported after a haemodialysis patient had received both morphine and cimetidine.

• Diuretics: Morphine reduces the efficacy of diuretics by inducing the release of antidiuretic hormone. Morphine may also lead to acute retention of urine by causing spasm of the sphincter of the bladder, particularly in men with prostatism.

• Alcohol: enhanced sedative and hypotensive effect.

• Anti-Arrhythmtics: delayed absorption of mexiletine.

• Antidepressants: CNS excitation or depression (hypertension or hypotension) if pethidine and possibly other opioid analgesic are given to patients receiving MAOIs (including moclobemide).

• Anxiolytics and Hypnotics: enhanced sedative effect.

• Cisapride: possible antagonism of gastro-intestinal effect.

• Domperidone and metoclopramide: antagonism of gastro-intestinal effects.

• Dopaminergics: hyperpyrexia and CNS toxicity reported with selegiline.

• Rifampicin: Plasma concentrations of morphine may be reduced by rifampicin. The analgesic effect of morphine should be monitored and doses of morphine adjusted during and after treatment with rifampicin (see section 4.4).

4.6 Fertility, pregnancy and lactation


Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.

If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Animal reproduction studies have shown that morphine can cause foetal damage when administered throughout pregnancy. An association with increased frequency of inguinal hernias in Infants has been postulated in man. Pregnant patients should only be given morphine when the benefits clearly outweigh potential risks to the foetus.

Newborns whose mothers received opioid analgesics during pregnancy should be monitored for signs of neonatal withdrawal (abstinence) syndrome. Treatment may include an opioid and supportive care.

Use in labour / delivery

Infants born to mothers receiving opioid analgesics during labour should be observed closely for signs of respiratory depression. In such infants a specific opioid antagonist, naloxone hydrochloride, should be readily available for reversal of narcotic-induced respiratory depression. After chronic morphine use by the mother, new-borns may develop withdrawal symptoms.

Morphine may prolong labour by temporarily reducing the strength, duration and frequency of uterine contractions. Conversely, it may tend to shorten labour by increasing the rate of cervical dilatation.


Administration to nursing women is not recommended as morphine may be secreted in breast milk and may cause respiratory depression in the infant. Withdrawal syndrome was observed in breast-fed infants after maternal administration of morphine had been stopped.


Animal studies have shown that morphine may reduce fertility (see 5.3. preclinical safety data).

4.7 Effects on ability to drive and use machines

Morphine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a car or operating machinery. Morphine in combination with other narcotic analgesics, phenothiazines, sedative-hypnotics, and alcohol have additive depressant effects.

Patients should not drive or operate machinery

Details regarding a new driving offence concerning driving after drugs have been taken in the UK may be found here:

This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:

The medicine is likely to affect your ability to drive

Do not drive until you know how the medicine affects you

It is an offence to drive while under the influence of this medicine

However, you would not be committing an offence (called 'statutory defence') if:

o The medicine has been prescribed to treat a medical or dental problem and

o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and

o It was not affecting your ability to drive safely

4.8 Undesirable effects

The following frequency categories form the basis for classification of the undesirable effects:



Very common

≥ 1/10


≥ 1/100 to <1/10


≥ 1/1,000 to <1/100


≥1/10,000 to <1/1,000

Very rare


Frequency not known

Cannot be estimated from the available data

Very common:

Gastrointestinal system: Nausea, vomiting, constipation.

Respiratory system: Respiratory depression.

Nervous system disorders: Sedation, drowsiness.

Skin: Itching.

Psychiatric disorders: Disorientation, hallucinations, dysphoria, euphoria, tolerance.


Skin: Urticaria, skin rash, pain at injection site, contact dermatitis.

CNS and nervous system: Headache, vertigo, agitation, convulsions, impairment of taste, mood changes, changes of cognitive and sensory abilities, insomnia, intracranial hypertension, tremor.

Musculoskeletal system: Muscle spasms.

Eye: Miosis, visual disturbances (blurred vision, nystagmus, diplopia).

Gastrointestinal system: Dryness of mouth, pylorospasm, singultus, diarrhoea, abdominal cramps, biliary colic.

Cardiovascular system: Flushing, chills, orthostatic hypotension, bradycardia, hypertension, tachycardia, heart failure, pulmonary oedema.

Respiratory system: Laryngeal spasm, bronchospasm, cough attenuation.

Urogenital system: Urinary retention or hesitancy, oliguria, loss of libido, impotence.

Endocrine: Inappropriate antidiuretic hormone (ADH) secretion characterised by hyponatraemia secondary to decreased free water excretion.

General: Oedema, hypothermia, hyperthermia.

Pulmonary oedema after overdose is a common cause of fatalities among opioid addicts.

Morphine and some other opioids have a dose-related histamine effect, which may be responsible in part for reactions such as urticaria and pruritis as well as hypotension and flushing. Contact dermatitis has been reported and pain and irritation may occur on injection. Anaphylactic reactions following intravenous injection have been reported rarely.


Immune system disorders: Anaphylactic / anaphylactoid reaction after i.v. injection.

General: Drug withdrawal syndrome.

Frequency not known:

Nervous system disorders: allodynia, hyperalgesia, hyperhidrosis (see section 4.4)

Psychiatric disorders: Drug dependence (see section 4.4)

Drug dependence and withdrawal (abstinence) syndrome

Use of opioid analgesics may be associated with the development of physical and/or psychological dependence or tolerance. An abstinence syndrome may be precipitated when opioid administration is suddenly discontinued or opioid antagonists administered, or can sometimes be experienced between doses. For management, see section 4.4.

Physiological withdrawal symptoms include: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose


Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.

Overdosage with morphine is characterised by respiratory depression (a decrease in respiratory rate, potentially leading to fatal respiratory failure, and/or tidal volume, Cheyne-Stokes respiration, cyanosis), pneumonia aspiration, pinpoint pupils, extreme somnolence progressing to stupor and coma, skeletal muscle flaccidity, cold and clammy skin and sometimes bradycardia and hypotension. In severe overdosage, apnoea, circulatory collapse, cardiac arrest and death may occur.


Immediate attention should be given to the re-establishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. Oxygen, intravenous fluid, vasopressors and other supportive measures should be employed as indicated.

The narcotic antagonist, naloxone, is a specific antidote for morphine. The recommended adult dose of naloxone is 0.4 to 2.0 mg IV every 2 to 3 minutes as necessary, simultaneously with assisted respiration. For children, the initial recommended dose is 0.01 mg/kg naloxone. A response should be seen after 2-3 doses. Note that the duration of action of naloxone is usually shorter than that of morphine and thus patients should be carefully monitored for signs of CNS depression returning.

If the response to naloxone is suboptimal or not sustained, additional naloxone may be administered as needed to maintain alertness and respiratory function. There is no additional information available about the cumulative dose of naloxone that may be safely administered.

To sustain opioid antagonism, an intravenous infusion of naloxone has been suggested. Naloxone may be infused at a rate titrated in accordance with the patient's response both to the infusion and previous bolus injections.

Naloxone should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to morphine overdosage. It should be administered cautiously to persons who are known or suspected to be physically dependant to morphine. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute withdrawal syndrome. The severity of the withdrawal syndrome will depend on the degree of physical dependence and the dose of the antagonist administered. If it is necessary to treat serious respiratory depression in the physically dependent patient, the antagonist should be administered with extreme care and by titration with smaller than usual doses of the antagonist.

Morphine toxicity may be the result of overdosage but because of the large inter-individual variation in sensitivity to opioids it is difficult to assess the exact dose of any opioid that is toxic or lethal. The toxic effects of morphine tend to be overshadowed by the presence of pain or tolerance. Patients receiving chronic morphine therapy have been known to take in excess of 3000 mg/day with no apparent toxic effect.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Morphine is pharmacologically the most important alkaloid of opium. It is used primarily as an analgesic for severe pain.

The analgesic effect of morphine is primarily due to an interaction with the OP3(u)-receptor, one of three major classes of opioid receptors that can be distinguished in the central nervous system. The metabolite morphine-6-glucuronide also acts as an agonist on opioid-receptors and contributes significantly to the pharmacological effects of chronic morphine treatment. Doses of 0.1 mg/kg body-weight of morphine and higher are effective in various animal analgesic tests.

Morphine causes respiratory depression by diminishing the response of the respiratory centres to CO2. This effect is mediated by the action on OP3-receptors and can be antagonised by naloxone.

Morphine stimulates the chemo-receptor trigger zone by action on dopamine- receptors and may cause nausea and vomiting.

Other effects: Morphine can induce euphoria and miosis. Hypotension may occur due to increased histamine release, especially in hypovolaemic patients.

5.2 Pharmacokinetic properties

Approximately 35 % of morphine is bound to plasma proteins. Morphine is rapidly metabolized. Approximately 50 % is converted to the major metabolite, the pharmacologically inactive morphine-3-glucuronide and 10-15 % is converted to the active morphine-6-glucuronide. Further metabolites include a diglucuronide, normorphine and its glucuronides. Approximately 60% of morphine is excreted in the urine in 24 hours, of which less than 10% of the dose is excreted as unchanged drug.

5.3 Preclinical safety data

In male rats, reduced fertility and chromosomal damage in gametes have been reported.

6. Pharmaceutical particulars
6.1 List of excipients

Sodium chloride,

hydrochloric acid,

water for injections,


6.2 Incompatibilities

Morphine sulfate is physically incompatible with aciclovir sodium, aminophylline, amobarbital sodium, cefepime hydrochloride, chlorothiazide sodium, floxacillin sodium, furosemide, gallium nitrate, heparin sodium, meperidine hydrochloride, meperidine sodium, methicillin sodium, minocycline hydrochloride, pentobarbital sodium, phenobarbital sodium, phenytoin sodium, sargramostim, sodium bicarbonate, thiopental sodium.

Physicochemical incompatibility (formation of precipitates) has been demonstrated between solutions of morphine sulfate and 5- fluorouracil.

6.3 Shelf life

3 years

6.4 Special precautions for storage

Do not store above 25°C. Keep the ampoule in the outer carton in order to protect from light.

6.5 Nature and contents of container

1 ml colourless glass DIN ampoules, glass type I Ph Eur, packed in cardboard cartons and containing 10 x 1 ml ampoules.

6.6 Special precautions for disposal and other handling

For Single Dose Use Only. Discard any unused solution immediately and safely after initial use.

7. Marketing authorisation holder

hameln pharma ltd


Gloucester Business Park



United Kingdom

8. Marketing authorisation number(s)

PL 01502/0063

9. Date of first authorisation/renewal of the authorisation

10th February 2005

10. Date of revision of the text